Tradestie Institutional Equity Comparison Engine
VIVS vs ENTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ENTX Overall Edge
ENTX Captures Institutional Edge (3โ0 Pillars ยท 6โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Entera Bio Ltd. Ordinary Shares (ENTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, VIVS trades at N/M Forward P/E with -10117.0% operating margin (-51.4% YoY revenue) versus ENTX at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, VIVS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against ENTX sits in CONSOLIDATION (33rd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
VIVS N/M vs ENTX N/M Fwd P/E
Growth & Margin Winner
ENTX
Op Margin -10117.0% vs 0.0% ยท YoY -51.4% vs -100.0%
Momentum & Technical Winner
ENTX
1Y -87.0% vs +26.1% ยท 52W Pos 5% vs 72%
Options & Structure Winner
ENTX
BREAKDOWN (N/A IV) vs CONSOLIDATION (33rd %ile IV)
VIVS
NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap
$2.4M
1M Return
+64.69%
1Y Return
-86.99%
Forward P/E
N/M
Unified AI Score
36.8 / 100
SELL
Tech 5.0
Fund 38.0
Flow 50.0
Mom 50.0
ENTX
NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.28
+0.61% 1D
Market Cap
$567.7M
1M Return
+7.54%
1Y Return
+26.15%
Forward P/E
N/M
Unified AI Score
45.2 / 100
HOLD
Tech 25.0
Fund 51.0
Flow 68.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
VIVS -86.99%
ENTX +26.15%
Spread: +113.14 pp (ENTX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VIVS Revenue | ENTX Revenue | VIVS Op. Margin | ENTX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $0M | N/A | -882.4% | N/A | VIVS |
| FY2020 | $0M | $0M | -977.9% | -3059.7% | VIVS |
| FY2021 | N/A | $0M | N/A | -2139.6% | ENTX |
| FY2022 | $0M | $0M | -765.3% | -9714.2% | VIVS |
| FY2023 | $0M | N/A | -4792.2% | N/A | VIVS |
| FY2024 | $0M | $0M | -13840.4% | -5295.6% | ENTX |
| FY2025 | $0M | $0M | -8761.1% | -27450.0% | VIVS |
| FY2026 | $0M | N/A | -8768.7% | N/A | VIVS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VIVS | ENTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.4M | $567.7M | Larger Scale | ENTX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -51.4% | -100.0% | Higher Growth | VIVS |
| Operating Margin (TTM) Profitability | -10117.0% | 0.0% | Higher Margin | ENTX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -343.1% | -20.3% | Higher ROE | ENTX |
| 52-Week Range Position Momentum | 5% ($0โ$3) | 72% ($1โ$4) | Stronger Trend | ENTX |
| Beta / 30D Volatility Risk Regime | 0.83ฮฒ ยท 480% Vol | 1.00ฮฒ ยท 54% Vol | Lower Realized Risk | ENTX |
| Unified Institutional Score Composite Signal | 36.8 / 100 (SELL) | 45.2 / 100 (HOLD) | Higher Composite | ENTX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full VIVS vs ENTX Buy Guide
VIVS
BREAKDOWN
73d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ENTX
CONSOLIDATION
82d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
33rd %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither VIVS nor ENTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.